$Bob's and Jbem's Bitchin' Bios

[Lady_luck]

TPIV may start heating up again. Several key catalyst are coming up.


3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200
3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women
with advanced triple-negative breast cancer
3Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC
4Q 2017: TPIV 100/110 File amended IND; initate phase 1b/2 HER2/neu + breast cancer study
4Q 2017/1Q 2018- TPIV100/110 Mayo Clinic to initate Phase 1b/2 HER2/nue + DCIS study
Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer.


Additionally:
ACCRU study is now listed as status= "OPEN" (RU011501I)

https://ncctg.mayo.edu/training/registration_loc.html
http://www.accru.org/web_updates/Newsletters/Fall_2016.pdf (see page 5)

This trial is listed under other study id for NCT03012100
https://clinicaltrials.gov/ct2/show/NCT03012100


Responsible Party: Academic and Community Cancer Research United
ClinicalTrials.gov Identifier: NCT03012100 History of Changes
Other Study ID Numbers: RU011501I
NCI-2016-01878 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
RU011501I ( Other Identifier: Academic and Community Cancer Research United )
P30CA015083 ( U.S. NIH Grant/Contract )